Clinical Hold of DYNE-251

On January 14^th 2022, the U.S. FDA placed a clinical hold on Dyne’s Investigational New Drug (IND) submission for the launch of their clinical trial of DYNE-251, which targets Duchenne mutations amenable to skipping exon 51. You can read Dyne’s letter to the Duchenne community regarding the nature of this pre-clinical hold and their urgent continuing commitment to bring DYNE-251 to the clinic below: